Abstract:Proteolysis-targeting chimeras (PROTACs), which can selectively induce the degradation of target proteins, represent an attractive technology in drug discovery. A large number of PROTACs have been reported, but due to the complicated structural and kinetic characteristics of the target-PROTAC-E3 ligase ternary interaction process, the rational design of PROTACs is still quite challenging. Here, we characterized and analyzed the kinetic mechanism of MZ1, a PROTAC that targets the bromodomain (BD) of the bromodomain and extra terminal (BET) protein (Brd2, Brd3, or Brd4) and von Hippel-Lindau E3 ligase (VHL), from the kinetic and thermodynamic perspectives of view by using enhanced sampling simulations and free energy calculations. The simulations yielded satisfactory predictions on the relative residence time and standard binding free energy (rp > 0.9) for MZ1 in different BrdBD-MZ1-VHL ternary complexes. Interestingly, the simulation of the PROTAC ternary complex disintegration illustrates that MZ1 tends to remain on the surface of VHL with the BD proteins dissociating alone without a specific dissociation direction, indicating that the PROTAC prefers more to bind with E3 ligase at the first step in the formation of the target-PROTAC-E3 ligase ternary complex. Further exploration of the degradation difference of MZ1 in different Brd systems shows that the PROTAC with higher degradation efficiency tends to leave more lysine exposed on the target protein, which is guaranteed by the stability (binding affinity) and durability (residence time) of the target-PROTAC-E3 ligase ternary complex. It is quite possible that the underlying binding characteristics of the BrdBD-MZ1-VHL systems revealed by this study may be shared by different PROTAC systems as a general rule, which may accelerate rational PROTAC design with higher degradation efficiency.

The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Discovery of E3 Ligase Ligands for Target Protein Degradation

Clinical considerations for the design of PROTACs in cancer

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Targeted protein degradation: expanding the toolbox

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Identification of Suitable Target/E3 Ligase Pairs for PROTAC Development using a Rapamycin-induced Proximity Assay (RiPA)

Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera

Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Uncovering the Kinetic Characteristics and Degradation Preference of PROTAC Systems with Advanced Theoretical Analyses

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

The Present and Future of Novel Protein Degradation Technology

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

E3 ligase ligand optimization of Clinical PROTACs

An overview of PROTACs: a promising drug discovery paradigm